3C-like protease inhibitor
|
ChEBI
|
3C-like protease inhibitors
|
ChEBI
|
3cLpro inhibitor
|
ChEBI
|
3cLpro inhibitors
|
ChEBI
|
coronavirus 3C-like protease inhibitor
|
ChEBI
|
coronavirus 3C-like protease inhibitors
|
ChEBI
|
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitors
|
ChEBI
|
EC 3.4.22.69 inhibitor
|
ChEBI
|
EC 3.4.22.69 inhibitors
|
ChEBI
|
Mpro inhibitor
|
ChEBI
|
Mpro inhibitors
|
ChEBI
|
SARS 3C-like protease inhibitor
|
ChEBI
|
SARS 3C-like protease inhibitors
|
ChEBI
|
SARS coronavirus 3CL protease inhibitor
|
ChEBI
|
SARS coronavirus 3CL protease inhibitors
|
ChEBI
|
SARS coronavirus main peptidase inhibitor
|
ChEBI
|
SARS coronavirus main peptidase inhibitors
|
ChEBI
|
SARS coronavirus main protease inhibitor
|
ChEBI
|
SARS coronavirus main protease inhibitors
|
ChEBI
|
SARS coronavirus main proteinase inhibitor
|
ChEBI
|
SARS coronavirus main proteinase inhibitors
|
ChEBI
|
SARS-CoV 3CLpro enzyme inhibitor
|
ChEBI
|
SARS-CoV 3CLpro enzyme inhibitors
|
ChEBI
|
SARS-CoV main protease inhibitor
|
ChEBI
|
SARS-CoV main protease inhibitors
|
ChEBI
|
SARS-CoV Mpro inhibitor
|
ChEBI
|
SARS-CoV Mpro inhibitors
|
ChEBI
|
severe acute respiratory syndrome coronavirus main protease inhibitor
|
ChEBI
|
severe acute respiratory syndrome coronavirus main protease inhibitors
|
ChEBI
|